Found: 8
Select item for more details and to access through your institution.
RETREATMENT WITH NIVOLUMAB IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA AFTER DISCONTINUATION OF THE THERAPY WITH IMMUNE CHECKPOINT INHIBITORS.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 496, doi. 10.1002/hon.176_2631
- By:
- Publication type:
- Article
RESPONSE TO NIVOLUMAB AS ≥3<sup>rd</sup> LINE THERAPY IN PTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (CHL) AND ITS IMPACT ON QUALITY OF LIFE IN RESPONDERS AND NONRESPONDERS.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 495, doi. 10.1002/hon.174_2631
- By:
- Publication type:
- Article
INFECTIOUS COMPLICATIONS OF NIVOLUMAB THERAPY IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 502, doi. 10.1002/hon.184_2631
- By:
- Publication type:
- Article
TREATMENT OF RELAPSED AND REFRACTORY T‐CELL LYMPHOMAS: FIRST PAVLOV STATE MEDICAL UNIVERSITY OF SAINT‐PETERSBURG EXPERIENCE.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 473, doi. 10.1002/hon.152_2631
- By:
- Publication type:
- Article
INFECTIOUS COMPLICATIONS OF NIVOLUMAB THERAPY IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 502, doi. 10.1002/hon.184_2631
- By:
- Publication type:
- Article
RETREATMENT WITH NIVOLUMAB IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA AFTER DISCONTINUATION OF THE THERAPY WITH IMMUNE CHECKPOINT INHIBITORS.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 496, doi. 10.1002/hon.176_2631
- By:
- Publication type:
- Article
RESPONSE TO NIVOLUMAB AS ≥3<sup>rd</sup> LINE THERAPY IN PTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (CHL) AND ITS IMPACT ON QUALITY OF LIFE IN RESPONDERS AND NONRESPONDERS.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 495, doi. 10.1002/hon.174_2631
- By:
- Publication type:
- Article
TREATMENT OF RELAPSED AND REFRACTORY T‐CELL LYMPHOMAS: FIRST PAVLOV STATE MEDICAL UNIVERSITY OF SAINT‐PETERSBURG EXPERIENCE.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 473, doi. 10.1002/hon.152_2631
- By:
- Publication type:
- Article